Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
0.9875
USD
|
+1.83%
|
|
+1.75%
|
+2.60%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
124.6
|
302.5
|
558.5
|
163.8
|
85.56
|
88.51
|
-
|
-
|
Enterprise Value (EV)
1 |
124.6
|
302.5
|
558.5
|
163.8
|
85.56
|
88.51
|
88.51
|
88.51
|
P/E ratio
|
-1
x
|
-6.9
x
|
-3.15
x
|
0.96
x
|
-1.03
x
|
-1.09
x
|
-0.97
x
|
-1.33
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.95
x
|
56.3
x
|
282
x
|
4.84
x
|
264
x
|
17.2
x
|
41.3
x
|
2.79
x
|
EV / Revenue
|
9.95
x
|
56.3
x
|
282
x
|
4.84
x
|
264
x
|
17.2
x
|
41.3
x
|
2.79
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-5.56
x
|
-3.49
x
|
-
|
-1.03
x
|
-0.99
x
|
-1.18
x
|
FCF Yield
|
-
|
-
|
-18%
|
-28.7%
|
-
|
-97.2%
|
-101%
|
-84.7%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
61,382
|
62,634
|
86,862
|
88,045
|
88,891
|
89,630
|
-
|
-
|
Reference price
2 |
2.030
|
4.830
|
6.430
|
1.860
|
0.9625
|
0.9875
|
0.9875
|
0.9875
|
Announcement Date
|
2/25/20
|
2/25/21
|
3/1/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
12.52
|
5.372
|
1.979
|
33.82
|
0.324
|
5.133
|
2.143
|
31.74
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-116
|
-44.52
|
-90.51
|
-60.39
|
-93.06
|
-89.78
|
-103
|
-82.14
|
Operating Margin
|
-926.46%
|
-828.67%
|
-4,573.52%
|
-178.53%
|
-28,723.77%
|
-1,748.92%
|
-4,808.33%
|
-258.81%
|
Earnings before Tax (EBT)
1 |
-112.6
|
-43.52
|
-173.2
|
172.2
|
-82.1
|
-80.13
|
-97.46
|
-77.71
|
Net income
1 |
-112.6
|
-43.52
|
-173.2
|
172.2
|
-82.1
|
-81.05
|
-97.46
|
-75.03
|
Net margin
|
-899.24%
|
-810.16%
|
-8,753.71%
|
509.01%
|
-25,337.96%
|
-1,578.94%
|
-4,547.89%
|
-236.4%
|
EPS
2 |
-2.030
|
-0.7000
|
-2.040
|
1.940
|
-0.9300
|
-0.9043
|
-1.021
|
-0.7400
|
Free Cash Flow
1 |
-
|
-
|
-100.4
|
-46.94
|
-
|
-86
|
-89
|
-75
|
FCF margin
|
-
|
-
|
-5,075.19%
|
-138.77%
|
-
|
-1,675.33%
|
-4,153.33%
|
-236.31%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/25/21
|
3/1/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.046
|
0.015
|
0.44
|
32.56
|
0.814
|
0.283
|
0.026
|
0.011
|
0.004
|
-
|
0.2229
|
0.2229
|
8.079
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-39.53
|
-24.77
|
-23.45
|
11.65
|
-23.81
|
-24.22
|
-21.35
|
-26.69
|
-20.81
|
-24.39
|
-23.7
|
-24.15
|
-17.03
|
-
|
-
|
Operating Margin
|
-85,939.13%
|
-165,140%
|
-5,328.86%
|
35.77%
|
-2,925.55%
|
-8,557.6%
|
-82,107.69%
|
-242,627.27%
|
-520,250%
|
-
|
-10,635.76%
|
-10,834.67%
|
-210.79%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-39.5
|
-24.77
|
-23.47
|
241.5
|
-21.08
|
-21.37
|
-18.58
|
-23.99
|
-18.16
|
-21.87
|
-21.58
|
-22.12
|
-15.47
|
-
|
-
|
Net income
1 |
-39.5
|
-24.77
|
-23.47
|
241.4
|
-20.96
|
-21.37
|
-18.58
|
-23.99
|
-18.16
|
-21.87
|
-21.58
|
-22.12
|
-15.47
|
-
|
-
|
Net margin
|
-85,865.22%
|
-165,113.33%
|
-5,333.64%
|
741.4%
|
-2,574.94%
|
-7,551.94%
|
-71,446.15%
|
-218,054.55%
|
-454,025%
|
-
|
-9,681.99%
|
-9,926.03%
|
-191.44%
|
-
|
-
|
EPS
2 |
-0.4500
|
-0.2800
|
-0.2700
|
2.750
|
-0.2400
|
-0.2400
|
-0.2100
|
-0.2700
|
-0.2000
|
-0.2500
|
-0.2357
|
-0.2457
|
-0.1729
|
-0.2300
|
-0.2400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/16/22
|
8/8/22
|
11/3/22
|
3/2/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/29/24
|
5/1/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-100
|
-46.9
|
-
|
-86
|
-89
|
-75
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.16
|
0.06
|
0.21
|
0.07
|
-
|
0.06
|
0.05
|
0.05
|
Capex / Sales
|
1.26%
|
1.08%
|
10.46%
|
0.21%
|
-
|
1.11%
|
2.33%
|
0.16%
|
Announcement Date
|
2/25/20
|
2/25/21
|
3/1/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
0.9875
USD Average target price
7
USD Spread / Average Target +608.86% Consensus |
1st Jan change
|
Capi.
|
---|
| +2.60% | 88.51M | | +9.42% | 115B | | +11.84% | 106B | | -1.05% | 21.96B | | -14.15% | 21.87B | | -5.29% | 19.21B | | -4.16% | 18.08B | | -38.29% | 17.71B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|